CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
Capricor Therapeutics, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”) on June 8, 2018 at the Company’s principal executive offices located at 8840 Wilshire Blvd., Beverly Hills, California 90211.At the Annual Meeting, the Company’s stockholders were asked to vote upon the following two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2018:
| 1. | The election of seven nominees to the Company’s Board of Directors to serve until the 2019 annual meeting of stockholders. The nominees for election were Frank Litvack, M.D., Linda Marbán, Ph.D., David B. Musket, George W. Dunbar, Jr., Louis Manzo, Earl M. (Duke) Collier, Jr. and Joshua Kazam; and |
| 2. | The ratification of the appointment by the Audit Committee of the Company’s Board of Directors of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. |
The final results of the matters voted on at the Annual Meeting, based on the presence in person or by proxy of holders of record of 23,260,771 shares of the 28,092,138 shares of the Company’s common stock entitled to vote, were as follows:
| 1. | The election of each of Dr. Litvack, Dr. Marbán, and Messrs. Musket, Dunbar, Manzo, Collier, and Kazam, as directors of the Company to serve until the 2019 annual meeting of stockholders, and until his or her successor is elected, or until his or her earlier death, resignation or removal, was approved as follows: |
| FOR | WITHHELD | BROKER NON-VOTES | |
| Frank Litvack, M.D. | 14,147,883 | 217,875 | 8,895,013 |
| Linda Marbán, Ph.D. | 14,268,153 | 97,605 | 8,895,013 |
| David B. Musket | 14,270,952 | 94,806 | 8,895,013 |
| George W. Dunbar, Jr. | 14,270,942 | 94,816 | 8,895,013 |
| Louis Manzo | 14,010,922 | 354,836 | 8,895,013 |
| Earl M. (Duke) Collier, Jr. | 13,134,187 | 1,231,571 | 8,895,013 |
| Joshua Kazam | 14,145,982 | 219,776 | 8,895,013 |
| 2. | The appointment by the Audit Committee of the Company’s Board of Directors of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 was ratified as follows: |
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
| 22,475,883 | 399,190 | 385,698 |
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
